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Abstract
Among antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV), granu-
lomatosis with polyangiitis (GPA) and proteinase 3-ANCA-positive AAV (PR3-AAV) are
prevalent in European populations, while microscopic polyangiitis (MPA) and myeloperoxi-
dase-ANCA-positive AAV (MPO-AAV) are predominant in the Japanese. We previously
demonstrated association of DRB1*09:01-DQB1*03:03 haplotype, a haplotype common in
East Asians but rare in the European populations, with MPA/MPO-AAV, suggesting that a
population difference in HLA-class II plays a role in the epidemiology of this disease. To
gain further insights, we increased the sample size and performed an extended association
study of DRB1 and DPB1 with AAV subsets in 468 Japanese patients with AAV classified
according to the European Medicines Agency algorithm (MPA: 285, GPA: 92, eosinophilic
GPA [EGPA]: 56, unclassifiable: 35) and 596 healthy controls. Among these patients, 377
were positive for MPO-ANCA and 62 for PR3-ANCA. The significance level was set at
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α = 3.3x10-4 by applying Bonferroni correction. The association of DRB1*09:01 with MPO-
AAV was confirmed (allele model, P = 2.1x10-4, odds ratio [OR] = 1.57). Protective associa-
tion of DRB1*13:02 was detected against MPO-AAV (allele model, P = 2.3x10-5, OR =
0.42) and MPA (dominant model, P = 2.7x10-4, OR = 0.43). A trend toward increased fre-
quency of DPB1*04:01, the risk allele for GPA in European populations, was observed
among Japanese patients with PR3-AAV when conditioned on DRB1*13:02 (Padjusted =
0.0021, ORadjusted = 3.48). In contrast, the frequency of DPB1*04:01 was decreased among
Japanese patients with MPO-AAV, and this effect lost significance when conditioned on
DRB1*13:02 (Padjusted = 0.16), suggesting that DRB1*13:02 or other allele(s) in linkage dis-
equilibrium may be responsible for the protection. The differential association of
DPB1*04:01 with PR3-AAV and MPO-AAV and difference in DPB1*04:01 allele frequen-
cies between populations supported the hypothesis that the HLA-class II population differ-
ence may account in part for these epidemiologic characteristics. Furthermore, taken
together with our previous observations, the haplotype carrying DRB1*13:02 was sug-
gested to be a shared protective factor against multiple autoimmune diseases.
Introduction
An epidemiologic difference is clearly observed in antineutrophil cytoplasmic antibody
(ANCA) -associated vasculitides (AAV) between European and East Asian populations. In a
population-based prospective study, microscopic polyangiitis (MPA) and myeloperoxidase
(MPO) -ANCA-positive AAV (MPO-AAV) were the predominant subtypes (>80%) in Japan,
while granulomatosis with polyangiitis (GPA) and proteinase 3 (PR3) -ANCA-positive AAV
(PR3-AAV) were the predominant subtypes (>60%) in the UK [1]. Differences in the genetic
backgrounds among populations may play a role in such epidemiologic differences.
Human leukocyte antigens (HLA) have been intensively investigated for association with
susceptibility to a number of autoimmune diseases. With respect to AAV in the populations of
European ancestry, candidate gene studies with relatively small sample sizes suggested an asso-
ciation of the DR4-DQ7 haplotype with the predisposition to both GPA and MPA in the UK
[2], of the DR1-DQ1 haplotype with GPA in the UK [3], and of DRB104 with end-stage renal
disease accompanied by GPA in Germany [4]. On the other hand, protective association of
DRB113 has been detected for GPA in Germany [4] and in the Netherlands [5]. Subsequently,
association of DPB104:01 with GPA has been reported in a moderately powered study in Ger-
many [6].
Recently, two large-scale genome-wide association studies (GWAS) on AAV in European
[7] and North American [8] populations detected the strongest associations in the major histo-
compatibility complex (MHC) region. In the European study, GPA and PR3-AAV showed the
strongest association in the HLA-DP region, while MPA and MPO-AAV demonstrated the
strongest association in the HLA-DQ region [7], which is generally in strong linkage disequilib-
rium (LD) with theHLA-DR region. Additionally, in the North American study (in which only
GPA was studied), the strongest association was observed in theHLA-DP region. Using impu-
tation, the investigators demonstrated that DPB104 is a risk allele group for GPA [8], support-
ing the results of a previous study in Germany [6].
Due to the rarity of AAV, few studies have examined the genetics in Asian populations. Our
group has been conducting a nationwide multicenter collaborative study of AAV in Japan.
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Thus far, we have reported the association of DRB109:01 and DQB103:03, which are in strong
LD, with MPA and MPO-AAV [9–11]. Curiously, while these risk haplotypes are among the
most frequent HLA-class II haplotypes in East Asian populations, these haplotypes are very
rare in populations of European or African ancestry (AlleleFrequencies in Worldwide Popula-
tions, http://www.allelefrequencies.net/) [12]. Thus, it is possible that ethnic differences in the
genetic backgrounds may be related to the differences in the incidence of AAV subsets.
Another remarkable feature of AAV in Japan was recently reported. Unlike in European
populations, approximately half of the patients who were classified into GPA according to
the European Medicines Agency (EMEA) algorithm [13] were positive for MPO-ANCA
[14]. Therefore, the comparison between Japanese and European populations of the genetic
backgrounds of patients with GPA will be of interest. With respect to GPA in Japan, only
one study with a very small sample size reported an association between GPA and DR9, and
that study was performed before the EMEA algorithm was proposed [15]. Furthermore,
19.9% of Japanese AAV patients who were eligible for classification by the EMEA algorithm
(based on ANCA positivity and symptoms and signs of AAV) nonetheless remained
“unclassifiable” according to the EMEA algorithm [14]. Interestingly, 93.5% of these unclas-
sifiable AAV patients were positive for MPO-ANCA, and 63.5% presented with interstitial
lung disease (ILD) [14], suggesting that this group may constitute a unique subset in the
AAV spectrum.
In the present study, we substantially increased the sample size of Japanese patients with
AAV from those of our previous studies, and performed an extended association analysis on
DRB1 and DPB1 with AAV in the Japanese population. Thus, the work described here allowed
us to assess whether additional DRB1 and DPB1 predispositional or protective alleles exist
for MPA and MPO-AAV, and whether DRB1 and/or DPB1 are associated with GPA and
PR3-AAV. HLA-DQA1 and DQB1 were not genotyped in this study, because these loci are in
strong LD with DRB1, making it highly difficult to distinguish associations of these alleles
based on the current sample size. Our observations indicated that DRB113:02 was associated
with protection against MPA and MPO-AAV. In agreement with a previous study in European
populations, association of DPB104:01 with the predisposition to PR3-AAV, but not with
MPO-AAV, was suggested in the Japanese population. Taken together with our previous
observations (which demonstrated protective association of DRB113:02 with rheumatoid
arthritis (RA) [16] and systemic lupus erythematosus (SLE) [17]), the haplotype carrying
DRB113:02 was suggested to be a common protective factor against multiple autoimmune
diseases.
Materials and Methods
Patients and controls
Four hundred and sixty-eight Japanese patients with AAV and 596 healthy controls, including
the 116 patients with MPO-AAV and 265 controls reported in our previous study [11], were
recruited at the institutes participating in the Research Committee on Intractable Vasculitides
and in the Research Group on Progressive Renal Diseases, both organized by the Ministry of
Health, Labour, and Welfare of Japan, research groups organized by Sagamihara Hospital,
National Hospital Organization, and the Tokyo Medical and Dental University. Information
on the patients and healthy individuals is shown in S1 Table. The patients were classified
according to the EMEA algorithm [13]. Two hundred and eighty-five cases were classified as
MPA, 92 as GPA, 56 as EGPA, and 35 were considered unclassifiable AAV. Among all patients,
377 and 62 were positive for MPO-ANCA and PR3-ANCA by ELISA, respectively.
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Hospital, Kitano Hospital, Shimane University, Nagoya City University, Ehime University,
Jichi Medical University, Kyoto Prefectural University, Tokyo Medical University Hachioji
Medical Center, Kitasato University Hospital, Hamamatsu University, National Hospital Orga-
nization Shimoshizu National Hospital, Tenri Hospital, Tokyo Metropolitan Geriatric Hospital
and Institute of Gerontology, Hyogo University, Kawasaki Municipal Hospital, Sendai Shakai-
hoken Hospital, Tokyo Women’s Medical College, Kyoundo Hospital, Tokyo Metropolitan
Komagome Hospital, Ome Municipal General Hospital, Teikyo University, Hokkaido Univer-
sity, Fukuoka University, Okayama Saiseikai General Hospital, Aichi Medical University, Asa-
hikawa Medical University, Kyushu University, Iwate Prefectural Central Hospital, and
Nagasaki University. Written informed consent was obtained from all participants, except for
some healthy individuals who donated blood (for use in medical genetics studies) before 2001,
that is, prior to the implementation by the Japanese government of the Ethics Guidelines for
Human Genome/Gene Analysis Research. From such healthy individuals, verbal informed
consent for the genetics study had been obtained. In accordance with the Japanese Ethical
Guidelines for Human Genome/Gene Analysis Research, such samples were anonymized in an
unlinkable fashion, and were included in this study after review and approval by the Ethics
Committee of the University of Tsukuba. This study was conducted according to the principles
expressed in the Declaration of Helsinki.
HLA allele typing
HLA-DRB1 and DPB1 genotypes were determined at the “four-digit” high-resolution level by
polymerase chain reaction (PCR) -microtiter plate hybridization or PCR-sequence-specific oli-
gonucleotide probes using WAKFlow HLA typing kits (Wakunaga Pharmaceutical Co., Ltd.,
Osaka, Japan). Amino acid sequences encoded by each DRB1 or DPB1 allele were based on the
IMGT/HLA Database (http://www.ebi.ac.uk/ipd/imgt/hla/) [18].
Statistical analysis
DRB1 and DPB1 alleles with frequencies  0.01 in healthy controls were examined for their
association with AAV subsets by Fisher's exact test in 2 x 2 contingency tables. When one of
the cell counts was zero, odds ratio (OR) and 95% confidence interval (CI) were calculated
with Haldane’s modification by adding 0.5 to each cell count. Correction for multiple testing
was done by Bonferroni correction. Statistical tests for 30 alleles (DRB1: 21, DPB1: 9) were car-
ried out for each of five AAV subsets (MPA, GPA, EGPA, MPO-AAV, and PR3-AAV). Thus,
the significance level was set at α = 3.3x10-4 (0.05/150). When a strong protective association
with one allele is present in a multiallelic locus like HLA, the predispositional association of the
other alleles tends to be overestimated, and the protective association of the other alleles tends
to be underestimated. In order to confirm whether the apparent predispositional allele is really
predispositional, and to detect additional predispositional or protective alleles, the relative pre-
dispositional effects (RPE) method was employed under the allele model, by consecutively
excluding the most strongly associated allele from the next-round analysis, until no allele
showed PRPE< 0.05 [19]. Conditional logistic regression analysis was performed to detect the
primary associated allele from the DRB1 and DPB1 alleles in LD. Association of each DRβ1
Protective Role of HLA-DRB1*13:02 in Japanese AAV
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and DPβ1 amino acid variant with frequencies 0.01 in the healthy controls was tested by
logistic regression analysis under the additive model. Statistical tests in 57 polymorphic amino
acid positions (DRβ1: 38, DPβ1: 19) were conducted for each of two AAV subsets (MPO-AAV
and PR3-AAV). Thus, in this analysis, the significance level was set at α = 4.4x10-4 (0.05/114)
using Bonferroni correction. When three or more amino acid variants are present at the same
position, only the P value for the comparison between the most strongly associated amino acid
and all other amino acid variants is shown. Statistical power in this study, calculated with the
PS (Power and Sample Size Calculation) program, is shown in S2 Table.
Results
HLA-DRB1
Association of DRB1 alleles with AAV was tested using clinical disease classification according
to the EMEA algorithm (Table 1 and S3 Table) as well as by ANCA specificity (Table 2 and S4
Table). This analysis permitted determination of the association of DRB109:01 with AAV in a
larger sample size than in our previous studies, along with assessment of the association of
other predispositional or protective DRB1 alleles with MPA and MPO-AAV. Predispositional
association of the DRB109:01 allele was confirmed in MPO-AAV (P = 2.1x10-4, OR = 1.57,
Table 1. HLA-DRB1 allele frequencies in Japanese patients with MPA, EGPA, or GPA or in healthy controls.
DRB1 MPA (2n = 570) EGPA (2n = 112) GPA (2n = 184) HC (2n = 1192)
n (%)a OR (95%CI) P n (%)a OR (95%CI) P n (%)a OR (95%CI) P n (%)a
01:01 41 (7.2) 1.24 (0.83–1.85) 0.30 8 (7.1) 1.23 (0.58–2.63) 0.53 14 (7.6) 1.32 (0.73–2.40) 0.41 70 (5.9)
04:01 6 (1.1) 0.74 (0.29–1.88) 0.66 0 (0.0) 0.30 (0.02–5.00)b 0.39 2 (1.1) 0.76 (0.17–3.31) 1.0 17 (1.4)
04:03 14 (2.5) 0.81 (0.43–1.51) 0.54 4 (3.6) 1.19 (0.42–3.40) 0.77 3 (1.6) 0.53 (0.16–1.75) 0.47 36 (3.0)
04:05 65 (11.4) 0.89 (0.65–1.21) 0.49 8 (7.1) 0.53 (0.25–1.11) 0.097 24 (13.0) 1.03 (0.65–1.64) 0.91 151 (12.7)
04:06 12 (2.1) 0.64 (0.33–1.22) 0.22 3 (2.7) 0.81 (0.25–2.68) 1.0 7 (3.8) 1.17 (0.51–2.65) 0.66 39 (3.3)
04:07 6 (1.1) 1.05 (0.39–2.80) 1.0 0 (0.0) 0.42 (0.02–7.14)b 0.61 2 (1.1) 1.08 (0.24–4.87) 1.0 12 (1.0)
04:10 9 (1.6) 1.11 (0.49–2.50) 0.83 3 (2.7) 1.90 (0.55–6.59) 0.24 4 (2.2) 1.54 (0.51–4.62) 0.51 17 (1.4)
08:02 21 (3.7) 1.34 (0.77–2.34) 0.30 1 (0.9) 0.32 (0.04–2.34) 0.35 13 (7.1) 2.67 (1.38–5.17) 0.0064 33 (2.8)
08:03 41 (7.2) 0.98 (0.67–1.45) 1.0 9 (8.0) 1.11 (0.54–2.27) 0.71 15 (8.2) 1.13 (0.64–2.00) 0.65 87 (7.3)
09:01 125 (21.9) 1.56 (1.21–2.01) 7.7E-04 24 (21.4) 1.51 (0.94–2.44) 0.10 35 (19.0) 1.30 (0.87–1.95) 0.19 182 (15.3)
11:01 16 (2.8) 1.61 (0.83–3.11) 0.16 3 (2.7) 1.53 (0.45–5.23) 0.45 5 (2.7) 1.56 (0.58–4.18) 0.38 21 (1.8)
12:01 17 (3.0) 0.73 (0.42–1.29) 0.34 4 (3.6) 0.88 (0.31–2.49) 1.0 2 (1.1) 0.26 (0.06–1.09) 0.054 48 (4.0)
12:02 8 (1.4) 0.72 (0.32–1.63) 0.56 2 (1.8) 0.92 (0.22–3.97) 1.0 1 (0.5) 0.28 (0.04–2.07) 0.24 23 (1.9)
13:02 25 (4.4) 0.47 (0.30–0.74) 6.3E-04 6 (5.4) 0.58 (0.25–1.35) 0.29 9 (4.9) 0.53 (0.26–1.06) 0.084 106 (8.9)
14:03 17 (3.0) 1.33 (0.72–2.45) 0.41 2 (1.8) 0.78 (0.18–3.34) 1.0 1 (0.5) 0.24 (0.03–1.75) 0.16 27 (2.3)
14:05 12 (2.1) 0.73 (0.38–1.43) 0.43 1 (0.9) 0.31 (0.04–2.26) 0.36 3 (1.6) 0.56 (0.17–1.86) 0.47 34 (2.9)
14:06 4 (0.7) 0.69 (0.22–2.16) 0.60 2 (1.8) 1.79 (0.40–8.09) 0.34 2 (1.1) 1.08 (0.24–4.87) 1.0 12 (1.0)
14:54 24 (4.2) 1.54 (0.90–2.64) 0.11 4 (3.6) 1.30 (0.45–3.74) 0.55 3 (1.6) 0.58 (0.18–1.92) 0.47 33 (2.8)
15:01 28 (4.9) 0.71 (0.46–1.10) 0.14 10 (8.9) 1.34 (0.68–2.67) 0.43 9 (4.9) 0.71 (0.35–1.43) 0.42 81 (6.8)
15:02 71 (12.5) 1.16 (0.85–1.58) 0.34 13 (11.6) 1.07 (0.59–1.97) 0.75 25 (13.6) 1.28 (0.81–2.03) 0.32 130 (10.9)
16:02 1 (0.2) 0.17 (0.02–1.33) 0.073 1 (0.9) 0.89 (0.11–6.88) 1.0 3 (1.6) 1.63 (0.46–5.83) 0.44 12 (1.0)
HC: healthy controls, OR: odds ratio, CI: conﬁdence interval. P values were calculated by Fisher’s exact test. Signiﬁcance level was set at α = 3.3x10-4 by
applying Bonferroni correction.
a n (%) indicates the number and percentage of each allele among the total number of alleles in each group (twice the number of individuals).
b OR and 95% CI were calculated using Haldane’s method when one of the cell counts was zero.
doi:10.1371/journal.pone.0154393.t001
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95%CI 1.24–1.98). In MPA, a trend for the association with this allele was detected
(P = 7.7x10-4, OR = 1.56, 95%CI 1.21–2.01), although the association failed to achieve statistical
significance after Bonferroni correction. Comparison of carrier frequency (dominant model)
demonstrated essentially the same results (S3 and S4 Tables).
In addition, significant protective association with DRB113:02 was newly detected against
MPO-AAV (allele model, P = 2.3x10-5, OR = 0.42, 95%CI 0.28–0.64, dominant model,
P = 1.1x10-5, OR = 0.39, 95%CI 0.25–0.60) and MPA (dominant model, P = 2.7x10-4,
OR = 0.43, 95%CI 0.26–0.68) (Table 2, S3 and S4 Tables). In order to exclude potential over-
and underestimation caused by strongly associated alleles in a multiallelic locus such as HLA,
the RPE method was employed. Thus, association of the other alleles was tested after excluding
the most strongly associated DRB113:02 allele from the patients and controls. In MPO-AAV,
the tendency toward positive association of DRB109:01 was still observed (PRPE = 0.0012)
(Table 2), suggesting that the predispositional association of DRB109:01 with MPO-AAV was
not a secondary phenomenon caused by protective association with DRB113:02.
With respect to other AAV subsets, a tendency toward positive association was detected
between GPA and DRB108:02 (P = 0.0064, OR = 2.67, 95%CI 1.38–5.17) (Table 1). Essentially
Table 2. HLA-DRB1 allele frequencies in Japanese patients with MPO-AAV or PR3-AAV or in healthy controls.
DRB1 MPO-AAV (2n = 754) PR3-AAV (2n = 124) HC (2n = 1192)
n (%)a OR (95%CI) P PRPE n (%)
a OR (95%CI) P n (%)a
01:01 56 (7.4) 1.29 (0.89–1.85) 0.19 0.30 8 (6.5) 1.11 (0.52–2.35) 0.84 70 (5.9)
04:01 7 (0.9) 0.65 (0.27–1.57) 0.40 0.30 2 (1.6) 1.13 (0.26–4.96) 0.70 17 (1.4)
04:03 18 (2.4) 0.79 (0.44–1.39) 0.48 0.33 2 (1.6) 0.53 (0.13–2.21) 0.57 36 (3.0)
04:05 74 (9.8) 0.75 (0.56–1.01) 0.059 0.020 17 (13.7) 1.10 (0.64–1.88) 0.78 151 (12.7)
04:06 24 (3.2) 0.97 (0.58–1.63) 1.0 0.79 1 (0.8) 0.24 (0.03–1.76) 0.17 39 (3.3)
04:07 7 (0.9) 0.92 (0.36–2.35) 1.0 0.82 2 (1.6) 1.61 (0.36–7.29) 0.39 12 (1.0)
04:10 12 (1.6) 1.12 (0.53–2.35) 0.85 1.0 3 (2.4) 1.71 (0.50–5.93) 0.43 17 (1.4)
08:02 36 (4.8) 1.76 (1.09–2.85) 0.023 0.044 2 (1.6) 0.58 (0.14–2.43) 0.77 33 (2.8)
08:03 51 (6.8) 0.92 (0.64–1.32) 0.72 0.47 14 (11.3) 1.62 (0.89–2.94) 0.11 87 (7.3)
09:01 166 (22.0) 1.57 (1.24–1.98) 2.1E-04* 0.0012 23 (18.5) 1.26 (0.78–2.04) 0.36 182 (15.3)
11:01 19 (2.5) 1.44 (0.77–2.70) 0.26 0.33 5 (4.0) 2.34 (0.87–6.33) 0.090 21 (1.8)
12:01 20 (2.7) 0.65 (0.38–1.10) 0.13 0.077 3 (2.4) 0.59 (0.18–1.93) 0.62 48 (4.0)
12:02 6 (0.8) 0.41 (0.17–1.01) 0.054 0.035 2 (1.6) 0.83 (0.19–3.58) 1.0 23 (1.9)
13:02 30 (4.0) 0.42 (0.28–0.64) 2.3E-05* - 9 (7.3) 0.80 (0.40–1.63) 0.62 106 (8.9)
14:03 21 (2.8) 1.24 (0.69–2.20) 0.55 0.65 0 (0.0) 0.17 (0.01–2.81)b 0.10 27 (2.3)
14:05 13 (1.7) 0.60 (0.31–1.14) 0.13 0.097 4 (3.2) 1.14 (0.40–3.25) 0.78 34 (2.9)
14:06 8 (1.1) 1.05 (0.43–2.59) 1.0 1.0 1 (0.8) 0.80 (0.10–6.20) 1.0 12 (1.0)
14:54 28 (3.7) 1.35 (0.81–2.26) 0.29 0.35 5 (4.0) 1.48 (0.57–3.85) 0.40 33 (2.8)
15:01 43 (5.7) 0.83 (0.57–1.21) 0.39 0.22 6 (4.8) 0.70 (0.30–1.63) 0.57 81 (6.8)
15:02 97 (12.9) 1.21 (0.91–1.60) 0.19 0.39 14 (11.3) 1.04 (0.58–1.87) 0.88 130 (10.9)
16:02 5 (0.7) 0.66 (0.23–1.87) 0.62 0.46 0 (0.0) 0.38 (0.02–6.44)b 0.62 12 (1.0)
HC: healthy controls, OR: odds ratio, CI: conﬁdence interval. P values were calculated by Fisher’s exact test. RPE: relative predispositional effect. RPE
analysis was performed by excluding DRB1*13:02 allele from cases and controls. P values considered signiﬁcant after Bonferroni correction (<3.3x10-4)
are shown in bold with an asterisk.
a n (%) indicates the number and percentage of each allele among the total number of alleles in each group (twice the number of individuals).
b OR and 95% CI were calculated using Haldane’s method when one of the cell counts was zero.
doi:10.1371/journal.pone.0154393.t002
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identical results were observed in the analysis of carrier frequency (dominant model) (S3 and
S4 Tables).
HLA-DPB1
Next, association ofHLA-DPB1 with clinical classification (Table 3 and S5 Table) and with
ANCA specificity (Table 4 and S6 Table) was examined. Protective association of DPB104:01
with MPO-AAV was detected (allele frequency: P = 2.1x10-4, OR = 0.40, 95%CI 0.24–0.67, car-
rier frequency: P = 1.2x10-4, OR = 0.38, 95%CI 0.22–0.64) (Table 4 and S6 Table). Essentially
the same results were observed in MPA (Table 3 and S5 Table). In RPE analysis, no significant
association of the other alleles was detected in MPO-AAV (Table 4).
Table 3. HLA-DPB1 allele frequencies in Japanese patients with MPA, EGPA, or GPA or in healthy controls.
DPB1 MPA (2n = 570) EGPA (2n = 112) GPA (2n = 184) HC (2n = 1186)
n (%)a OR (95%CI) P n (%)a OR (95%CI) P n (%)a OR (95%CI) P n (%)a
02:01 155 (27.2) 1.19 (0.94–1.49) 0.14 23 (20.5) 0.82 (0.51–1.32) 0.49 50 (27.2) 1.19 (0.83–1.68) 0.36 284 (23.9)
02:02 24 (4.2) 1.33 (0.79–2.24) 0.33 4 (3.6) 1.12 (0.39–3.19) 0.78 4 (2.2) 0.67 (0.24–1.90) 0.64 38 (3.2)
03:01 29 (5.1) 1.36 (0.84–2.19) 0.21 4 (3.6) 0.94 (0.33–2.66) 1.0 6 (3.3) 0.85 (0.36–2.03) 0.84 45 (3.8)
04:01 19 (3.3) 0.51 (0.31–0.85) 0.0090 2 (1.8) 0.27 (0.07–1.11) 0.057 14 (7.6) 1.22 (0.67–2.21) 0.52 75 (6.3)
04:02 73 (12.8) 1.44 (1.05–1.97) 0.025 14 (12.5) 1.40 (0.77–2.53) 0.31 19 (10.3) 1.13 (0.67–1.88) 0.68 110 (9.3)
05:01 183 (32.1) 0.77 (0.62–0.95) 0.015 43 (38.4) 1.01 (0.68–1.51) 1.0 64 (34.8) 0.87 (0.63–1.20) 0.41 452 (38.1)
09:01 64 (11.2) 1.10 (0.80–1.52) 0.56 11 (9.8) 0.95 (0.50–1.82) 1.0 19 (10.3) 1.00 (0.60–1.67) 1.0 122 (10.3)
13:01 6 (1.1) 0.56 (0.23–1.40) 0.31 5 (4.5) 2.47 (0.92–6.66) 0.076 1 (0.5) 0.29 (0.04–2.16) 0.35 22 (1.9)
14:01 8 (1.4) 0.79 (0.35–1.79) 0.69 0 (0.0) 0.24 (0.01–4.00)b 0.25 5 (2.7) 1.55 (0.58–4.16) 0.38 21 (1.8)
HC: healthy controls, OR: odds ratio, CI: conﬁdence interval, P values were calculated by Fisher’s exact test. Signiﬁcance level was set at α = 3.3x10-4 by
applying Bonferroni correction.
a n (%) indicates the number and percentage of each allele among the total number of alleles in each group (twice the number of individuals).
b OR and 95% CI were calculated using Haldane’s method when one of the cell counts was zero.
doi:10.1371/journal.pone.0154393.t003
Table 4. HLA-DPB1 allele frequencies in Japanese patients with MPO-AAV or PR3-AAV or in healthy controls.
DPB1 MPO-AAV (2n = 754) PR3-AAV(2n = 124) HC (2n = 1186)
na (%) OR (95%CI) P PRPE n
a (%) OR (95%CI) P na (%)
02:01 200 (26.5) 1.15 (0.93–1.41) 0.22 0.45 29 (23.4) 0.97 (0.63–1.50) 1.0 284 (23.9)
02:02 29 (3.8) 1.21 (0.74–1.98) 0.45 0.61 3 (2.4) 0.75 (0.23–2.46) 0.79 38 (3.2)
03:01 37 (4.9) 1.31 (0.84–2.04) 0.25 0.36 4 (3.2) 0.85 (0.30–2.39) 1.0 45 (3.8)
04:01 20 (2.7) 0.40 (0.24–0.67) 2.1E-04* - 14 (11.3) 1.89 (1.03–3.45) 0.057 75 (6.3)
04:02 91 (12.1) 1.34 (1.00–1.80) 0.056 0.094 14 (11.3) 1.24 (0.69–2.25) 0.42 110 (9.3)
05:01 255 (33.8) 0.83 (0.69–1.00) 0.059 0.011 45 (36.3) 0.93 (0.63–1.36) 0.77 452 (38.1)
09:01 88 (11.7) 1.15 (0.86–1.54) 0.37 0.50 9 (7.3) 0.68 (0.34–1.38) 0.35 122 (10.3)
13:01 10 (1.3) 0.71 (0.33–1.51) 0.47 0.37 0 (0.0) 0.21 (0.01–3.45)b 0.26 22 (1.9)
14:01 11 (1.5) 0.82 (0.39–1.71) 0.72 0.59 3 (2.4) 1.38 (0.40–4.68) 0.49 21 (1.8)
HC: healthy controls, OR: odds ratio, CI: conﬁdence interval. P values were calculated by Fisher’s exact test. RPE: relative predispositional effect. In
MPO-AAV, RPE was performed by excluding DPB1*04:01. P value considered signiﬁcant after Bonferroni correction (<3.3x10-4) is shown in bold with an
asterisk.
a n (%) indicates the number and percentage of each allele among the total number of alleles in each group (twice the number of individuals).
b OR and 95% CI were calculated using Haldane’s method when one of the cell counts was zero.
doi:10.1371/journal.pone.0154393.t004
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When the association between DPB1 and GPA/PR3-AAV was examined, DPB104:01 (the
risk allele for GPA in European populations) also showed a trend for association with predispo-
sition to PR3-AAV in the Japanese population (P = 0.057, OR = 1.89, 95%CI: 1.03–3.45)
(Table 4). An association with DPB104:01 was not observed for GPA (P = 0.52) (Table 3).
Conditional analysis of the DRB1*13:02 and DPB1*04:01 associations
in AAV subsets
DRB113:02 and DPB104:01 alleles, which are both negatively associated with MPO-ANCA,
were in moderate LD (r2 = 0.44). We therefore made an attempt to dissect these associations
using logistic regression analysis (Table 5).
In MPO-AAV, the protective association ofDPB104:01 lost significance when conditioned
on DRB113:02 (unconditioned P = 4.4x10-4, Padjusted = 0.16), while the tendency toward associa-
tion of DRB113:02 remained when conditioned onDPB104:01 (unconditioned P = 6.6x10-5,
Padjusted = 0.024). These results suggested that the protective association ofDPB104:01 with
MPO-AAV was secondary, and instead actually reflected LD withDRB113:02.
In contrast, although the association of DPB104:01 was barely detectable in PR3-AAV
(unconditioned P = 0.042), the tendency became apparent when conditioned on DRB113:02
(Padjusted = 0.0021). This observation suggested that DPB104:01, the risk allele for European
GPA, also may contribute to susceptibility to PR3-AAV in the Japanese population. Similarly,
DRB113:02 showed a tendency toward association after conditioning onDPB104:01 (Padjusted =
0.028). The direction of association was opposite forDPB104:01 (unconditioned OR = 1.86,
ORadjusted = 3.48) compared to DRB113:02 (unconditioned OR = 0.54, ORadjusted = 0.36). Thus,
it is likely that the associations ofDPB104:01 and DRB113:02 to PR3-AAV were attenuated by
each other due to LD, and therefore were underestimated before conditioning. The same ten-
dency also was observed in GPA after conditioning on the opposing allele. These results sug-
gested that the protective effect of DRB113:02may be present across all subsets of AAV, while
the predispositional effect ofDPB104:01may be present in PR3-AAV and GPA.
Table 5. Conditional logistic regression analysis betweenDRB1*13:02 andDPB1*04:01 in AAV subsets.
HLA allele unconditioned conditioned on DRB1*13:02 conditioned on DPB1*04:01
P OR (95%CI) Padjusted ORadjusted (95%CI) Padjusted ORadjusted (95%CI)
MPA
DRB1*13:02 0.0011 0.47 (0.30–0.73) N/A N/A 0.033 0.53 (0.29–0.93)
DPB1*04:01 0.011 0.51 (0.30–0.84) 0.57 0.83 (0.42–1.59) N/A N/A
GPA
DRB1*13:02 0.076 0.53 (0.25–1.01) N/A N/A 0.0066 0.29 (0.11–0.68)
DPB1*04:01 0.52 1.21 (0.65–2.11) 0.015 2.55 (1.17–5.48) N/A N/A
MPO-AAV
DRB1*13:02 6.6E-05 0.43 (0.28–0.64) N/A N/A 0.024 0.55 (0.32–0.91)
DPB1*04:01 4.4E-04 0.41 (0.24–0.66) 0.16 0.64 (0.33–1.18) N/A N/A
PR3-AAV
DRB1*13:02 0.54 0.80 (0.37–1.54) N/A N/A 0.028 0.36 (0.14–0.86)
DPB1*04:01 0.042 1.86 (0.99–3.30) 0.0021 3.48 (1.55–7.78) N/A N/A
OR: odds ratio, CI: conﬁdence interval, N/A: not applicable; P value, OR, and 95%CI and adjusted P value, OR, and 95%CI on the indicated HLA allele
were calculated by logistic regression analysis under the additive model.
doi:10.1371/journal.pone.0154393.t005
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Effects of DRB1 genotypes on MPO-AAV
Next, we calculated the OR for MPO-AAV with respect to DRB1 genotypes. To do this, we
classified each DRB1 allele into three categories corresponding to DRB109:01, DRB113:02,
and any remaining alleles (denoted by N for “neutral”). The results are shown in S1 Fig. When
compared with genotype N/N as the referent, DRB109:01/N was associated with predisposi-
tion (OR = 1.65, P = 0.0013) and 13:02/N with protection (OR = 0.45, P = 0.0019). Significant
association was not detected for 09:01/09:01 or 13:02/13:02, presumably due to the small
number of individuals homozygous for these alleles.
Association of amino acid variations in DRβ1
Finally, we investigated the association of each amino acid variation in the DRβ1 and DPβ1
proteins with MPO-AAV and PR3-AAV using logistic regression analysis under the additive
model. In DRβ1, 71E demonstrated the strongest association with the protection from
MPO-AAV (P = 2.6x10-5, OR = 0.41) (S2A Fig). When conditioned on 71E, only 67F showed
marginal predispositional association (Padjusted = 4.9x10
-4, OR = 1.46) (S2B Fig). When condi-
tioned on both 71E and 67F, no further significant association was detected (S2C Fig).
With respect to DPβ1, significant association (P = 4.1x10-4, OR = 0.47) of 36A and 55A,
which are in absolute LD, with MPO-ANCA was detected (S3A Fig). When conditioned on
36A, no further significant association was detected (S3B Fig).
Finally, because our observations indicated that the association of DPB104:01 with
MPO-AAV may be secondarily caused by DRB113:02, we examined the association of DPβ1
amino acids by conditioning on DRB113:02. With such conditioning, the association in DPβ1
amino acids was no longer significant (S3C Fig).
Significant association with PR3-ANCA was not detected for DRβ1 nor DPβ1 amino acids,
probably due to the small sample size.
Discussion
In this study, we performed a detailed analysis of the association ofHLA-DRB1 and DPB1
using the “four-digit” high-resolution allele typing on 468 Japanese patients with AAV and 596
healthy controls. To our knowledge, this sample size is (to date) the largest among the AAV
genetics studies reported for East Asian populations. In addition, the present work represents
the first study to examine DPB1 association with GPA in East Asian populations. In view of the
remarkable differences in the epidemiology and genetic background between the European
and East Asian populations [1], our study adds valuable information to the genetics research of
AAV.
We confirmed the previously reported association of DRB109:01 with MPO-AAV [9–11]
in an extended association study. Moreover, this study identified DRB113:02 as a protective
allele for MPO-AAV and MPA. Although the protective effect of DRB113 has previously been
reported for GPA or PR3-AAV in European populations [4,5], to our knowledge protective
association with MPA or MPO-AAV has not previously been clearly demonstrated. This dis-
crepancy likely reflects a lack of detection power due to the lower prevalence of MPO-AAV in
the European populations.
Notably, we recently reported the protective association of DRB113:02 against RA [16] and
SLE [17]. Thus, in sharp contrast to DRB109:01 (which also has been reported to be associated
with predisposition to RA [20,21], SLE [21], type 1 diabetes [22], and myasthenia gravis [23]),
DRB113:02 or other allele(s) in strong LD appears to have a protective effect against multiple
autoimmune rheumatic diseases.
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A recent study in a Chinese population reported association of DRB111:01 with susceptibil-
ity to MPA, but association of DRB109:01 was not detected [24]. In the present study,
although we detected a trend toward increased frequency of DRB111:01 in some subgroups of
AAV (Tables 1 and 2), this trend did not achieve statistical significance. We were unable to rep-
licate association of DRB114:54 with protection against overall AAV, nor DRB112:02 associa-
tion with predisposition to GPA in the Chinese [24]. The reasons for these discrepancies are
not clear, although differences inHLA allele frequencies in the general population might play a
role. In the Chinese study, the allele frequency of DRB111:01 in the control group was 6.5%
[24], which was considerably higher than the 1.8% allele frequency in the Japanese (Table 1).
In theMHC region, strong LD is detected. As for DRB1, strong LD is observed with DQB1.
DRB109:01 and DRB113:02 were in nearly absolute LD with DQB103:03 (r2 = 0.83) and
DQB106:04 (r2 = 0.89), respectively, in our healthy controls. This pattern makes it highly diffi-
cult to distinguish the association of the DRB1 alleles from that of the DQB1 alleles with the
present sample size. Therefore, our observations only indicate that the major genetic factor for
MPA/MPO-AAV is present in theHLA-DR/DQ region. This result is consistent with the find-
ing from the European GWAS, which demonstrated the strongest association signal for MPA/
MPO-AAV at a single nucleotide polymorphism (SNP) close to the DQB1 locus (rs5000634)
[7]. To fine-map the primary associated allele, the association study would need to be con-
ducted using a larger sample size.
With regards to DPB1, the present study suggested the possibility that the DPB104:01 allele
may be associated with PR3-AAV in the Japanese population, as in Caucasian populations
[6,8]. In contrast, DPB104:01 was protective against MPO-AAV, although this protection was
a secondary effect caused by LD with DRB113:02. In view of the striking population difference
in the DPB104:01 allele frequency in populations of Japanese (6.3%) (Table 3) and European
extraction (e.g., 42.5% in USA) (AlleleFrequencies in Worldwide Populations http://www.
allelefrequencies.net/) [12], DPB104:01may in part account for the epidemiologic difference
in the prevalence of PR3-AAV. In fact, as already pointed out by Watts et al. [25], population
allele frequency of DPB104:01 is higher in northern Europe than in southern Europe (S4 Fig)
based on AlleleFrequencies in Worldwide Populations http://www.allelefrequencies.net/)
[12]. On the other hand, the population allele frequencies of DRB109:01 and DQB103:03 are
low in both northern and southern Europe; no apparent north-south gradient is observed. Elu-
cidation of whether the north-south gradient ofHLA alleles can account for the geographic
variation in incidence of MPA and MPO-AAV in Europe will require identification ofHLA
alleles that can explain the GWAS signal of rs5000634 [7] in European populations.
When the associations identified in the present work were analyzed with respect to the
amino acid sequences, DRβ1 67F was associated with predisposition to, and 71E with protec-
tion against, MPO-AAV. Among the DRB1 alleles having allele frequencies> 1% in the Japa-
nese population, 67F is encoded by DRB108:02, 09:01, 11:01, and 12:02, while 71E is
encoded only by DRB113:02. Among the alleles encoding 67F, the frequencies of all except for
DRB112:02 were nominally or significantly higher in patients with MPO-AAV (Table 2).
Because amino acids at positions 67 and 71 influence antigenic peptide binding pockets P7 and
P4 (respectively) [26], it is possible that the antigenic peptide motifs of these alleles may be
involved in the molecular mechanism of association. On the other hand, the fact that
DRB109:01 and DRB113:02 are associated with susceptibility to or protection against multi-
ple autoimmune diseases with apparently no shared autoantigens suggests that a role is played
by the non-HLA alleles carried by these HLA haplotypes (rather than the antigenic peptide
specificity). These hypotheses are not mutually exclusive, and will require further investigation.
In the present study, associations generally appeared to be more prominent with ANCA
specificity than with clinical classification (e.g., DPB104:01 association with MPA: P = 0.0063,
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OR = 0.48; with MPO-AAV: P = 1.2x10-4, OR = 0.38; with GPA: P = 0.86, OR = 1.07; with
PR3-AAV: P = 0.12, OR = 1.71), consistent with the results obtained by GWAS in European
populations [7]. In this regard, it would be interesting to test the HLA association of the two
potentially unique subsets in Japan, MPO-ANCA-positive GPA and MPO-ANCA-positive
unclassifiable AAV [14], when sufficient numbers of samples become available. In the present
study, both of these AAV subsets were included in MPO-ANCA-positive subset; even after
excluding unclassifiable AAV from the analyses, the association of DRB109:01 (P = 1.8x10-4)
and DRB113:02 (P = 1.4x10-4) with MPO-AAV remained significant.
One of the most interesting findings in our study is that the haplotype carrying DRB113:02,
which we have reported to have protective association against RA [16] and SLE [17], is also
protective against MPA and MPO-AAV, suggesting that this haplotype carries a common pro-
tective allele with shared efficacy against different autoimmune diseases. Identification (by fine
mapping of the SNPs and deep sequencing) of the allele(s) responsible for the protection, and
of these allele(s)’ molecular mechanism(s) would not only lead to better understanding of the
etiopathogenesis of autoimmune diseases, but also to new molecular targets that could be effec-
tive for multiple autoimmune diseases.
There are several limitations in this study. Due to the rarity of AAV, this study is not an
independent replication of our previous studies [9–11], but is instead an extension study. A
replication study on a completely independent case-control set will be required to establish the
HLA associations with AAV in the Japanese.
The sample sizes of GPA, EGPA, and PR3-AAV are especially small, due to the low preva-
lence of these subsets in the Japanese. Therefore, our results on these subsets suffer from low
detection power (S2 Table), and significant associations may emerge when the sample size
becomes larger, especially for the alleles which showed uncorrected P values< 0.05 but did not
achieve significance following Bonferroni correction.
Another limitation is that we only focused on DRB1 and DPB1, and did not examine DQB1
(which is in strong LD with DRB1) or other HLA and non-HLA alleles. Therefore, at this point,
we cannot exclude the possibility that the associations detected for DRB1 and DPB1 alleles may
only tag other causal alleles. Such a possibility should be investigated in the future using high-
density SNP mapping, imputation, and/or sequencing of theMHC region.
In conclusion, in addition to confirming the predispositional association of DRB109:01
with MPO-AAV, this study identified the protective association of DRB113:02 against MPA
and MPO-AAV in the Japanese population. Taken together with our previous observations,
DRB113:02 itself (or another allele in LD with DRB113:02) was suggested to be a common
protective factor against multiple autoimmune diseases.
Supporting Information
S1 Fig. Association ofHLA-DRB1 genotypes with MPO-AAV. Each DRB1 allele was classi-
fied into DRB109:01 (predispositional), DRB113:02 (protective), or any of the remaining
alleles (denoted by N for neutral). Odds ratio, 95% confidence interval, and P value of each
genotype group were calculated against N/N. The numbers of patients and controls in each
group are shown below.
(PPTX)
S2 Fig. Association of DRβ1 amino acid variations with MPO-AAV. Association of each
amino acid residue in the DRβ1 protein with MPO-AAV was analyzed using logistic regression
analysis under the additive model. Amino acid residues with frequencies 0.01 in healthy con-
trols were examined for their association. The significance level was set at α = 4.4x10-4 using
Bonferroni correction. (A) Unconditioned P values (closed circles) are shown. When three or
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more amino acid variants are present at the same position, only the P value for the comparison
between the most strongly associated amino acid and all other amino acid variants is shown.
(B,C) P values conditioned on 71E (grey circles) and P values conditioned on 71E and 67F
(open circles) were calculated for the amino acid variants shown in S2A Fig.
(PPTX)
S3 Fig. Association of DPβ1 amino acid variations with MPO-AAV. Association of each
amino acid residue in the DPβ1 protein with MPO-AAV was analyzed using logistic regression
analysis under the additive model. Amino acid residues with frequencies 0.01 in healthy con-
trols were examined for their association. The significance level was set at α = 4.4x10-4 using
Bonferroni correction. (A) Unconditioned P values (closed circles) are shown. When three or
more amino acid variants are present at the same position, only the P value for the comparison
between the most strongly associated amino acid and all other amino acid variants is shown.
(B,C) P values conditioned on 36A (grey circles) and P values conditioned on DRB113:02
(open circles) were calculated for the amino acid variants shown in S3A Fig.
(PPTX)
S4 Fig. North-south gradient of population DPB104:01 allele frequency in Europeans.
DPB1 allele frequencies in European populations, aligned from north to south according to the
latitude. The data were derived from AlleleFrequencies in Worldwide Populations (http://
www.allelefrequencies.net/) [12].
(PPTX)
S1 Table. EMEA classification and ANCA specificity of the subjects. SD: standard deviation,
F: female, M: male, NA: not available.
(DOCX)
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